Serum tumor markers in breast cancer: are they of clinical value?
暂无分享,去创建一个
[1] J. Bergh,et al. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] B De La Lande,et al. Prognostic value of CA 15.3 kinetics for metastatic breast cancer. , 2002, The International journal of biological markers.
[3] K. Cheung,et al. Tumour marker measurements in the diagnosis and monitoring of breast cancer. , 2000, Cancer treatment reviews.
[4] M. Untch,et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer , 2002, British Journal of Cancer.
[5] M. Indelli,et al. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. , 1994, JAMA.
[6] R. Molina,et al. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. , 2003, Anticancer research.
[7] M. Duffy,et al. Preoperative CA 15‐3 concentrations predict outcome of patients with breast carcinoma , 1998, Cancer.
[8] A. Nicolini,et al. Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study. , 1997, British Journal of Cancer.
[9] M. Duffy,et al. CA 15-3 and Related Mucins as Circulating Markers in Breast Cancer , 1999, Annals of clinical biochemistry.
[10] C. Parker. Active surveillance: towards a new paradigm in the management of early prostate cancer. , 2004, The Lancet. Oncology.
[11] S. Ciatto,et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. , 1994, JAMA.
[12] A. Howell,et al. Objective measurement of therapeutic response in breast cancer using tumour markers. , 1991, British Journal of Cancer.
[13] A. Nicolini,et al. Postoperative Follow-Up of Breast Cancer Patients: Overview and Progress in the Use of Tumor Markers , 2000, Tumor Biology.
[14] Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Symeonidis,et al. Increased Serum CA-15.3 Levels in Patients with Megaloblastic Anemia due to Vitamin B12 Deficiency , 2005, Oncology.
[16] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.
[17] M. Duffy,et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. , 2004, Clinical chemistry.
[18] D. Kiang,et al. Tumor marker kinetics in the monitoring of breast cancer , 1990, Cancer.
[19] A. Cuschieri,et al. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer. , 1991, Journal of the Royal College of Surgeons of Edinburgh.
[20] G. Rustin,et al. Use of CA-125 to assess response to new agents in ovarian cancer trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Á. Ruibal,et al. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease , 1989, Cancer.
[22] B. Hancock,et al. Gestational trophoblastic diseases and their treatment. , 1997, Cancer treatment reviews.
[23] R. Neumann,et al. Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[24] Á. Ruibal,et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases , 1989, Breast Cancer Research and Treatment.
[25] R. Molina,et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value , 1998, Breast Cancer Research and Treatment.
[26] C. Vogel,et al. Trastuzumab plus chemotherapy: convincing survival benefit or not? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Dodwell,et al. Follow-up care of patients treated for breast cancer: a structured review. , 2004, Cancer treatment reviews.
[28] A. Vassou,et al. The neutrophil, not the tumor , 2004, Cancer.
[29] C. Isaacs,et al. New prognostic factors for breast cancer recurrence. , 2001, Seminars in oncology.
[30] M. Williams,et al. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. , 1990, British Journal of Cancer.
[31] R. Neumann,et al. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. , 2003, Clinical chemistry.
[32] F. Caponigro,et al. Impact of Preoperative CA 15-3 Levels in Operable Breast Cancer. Comparison with Tissue Polypeptide Antigen (TPA) and Carcinoembryonic Antigen (CEA) , 1991, The International journal of biological markers.
[33] E. Diamandis,et al. Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications , 2002 .
[34] R. Blamey,et al. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? , 1993, British Journal of Cancer.
[35] P. Dombernowsky,et al. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. , 1993, Clinical chemistry.
[36] H. Grimes,et al. The Prognostic Value of the Tumor Marker CA 15–3 at Initial Diagnosis of Patients with Breast Cancer , 2000, The International journal of biological markers.
[37] R. Motzer,et al. Testicular germ-cell cancer. , 1997, The New England journal of medicine.
[38] C. Sturgeon,et al. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes , 1996 .
[39] M. de las Heras,et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. , 2001, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[40] N. Dalay,et al. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena. , 1997, Clinical biochemistry.
[41] A. Liberati,et al. Follow-up strategies for women treated for early breast cancer. , 2005, The Cochrane database of systematic reviews.
[42] Farooq Ghani,et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies , 2004, Breast Cancer Research.
[43] R. Bast,et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] G. Mariani. New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] R. Blamey. Guidelines on endocrine therapy of breast cancer EUSOMA. , 2002, European journal of cancer.
[46] A. Howell,et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. , 1999, European Journal of Cancer.
[47] D. Seligson,et al. Clinical Chemistry , 1965, Bulletin de la Societe de chimie biologique.
[48] Martín Velasco,et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients , 2004, Breast Cancer Research and Treatment.
[49] L. Dogliotti,et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. , 1997, British Journal of Cancer.
[50] R. Gelber,et al. Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG) , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] M. Kurosumi,et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: A prospective study , 2004, Breast cancer.
[52] M. Duffy,et al. Predictive markers in breast and other cancers: a review. , 2005, Clinical chemistry.
[53] J. Geraghty,et al. CA 15‐3 in patients with locoregional and metastatic breast carcinoma , 1992, Cancer.
[54] A. Nicolini,et al. "Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. , 2003, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[55] L. Emens,et al. The follow-up of breast cancer. , 2003, Seminars in oncology.
[56] M. Duffy. Urokinase Plasminogen Activator and Its Inhibitor, Pai-1, as Prognostic Markers in Breast Cancer: from Pilot to Level 1 Evidence Studies , 2002 .
[57] A. Paccagnella,et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. , 2002, European journal of cancer.
[58] S. Ciatto,et al. Intensive Diagnostic Follow-up After Treatment of Primary Breast Cancer: A Randomized Trial , 1994 .
[59] F. Matsubara,et al. Changes in the tumor marker concentration in female patients with hyper-, eu-, and hypothyroidism. , 1989, Endocrinologia japonica.
[60] E. Kumpulainen,et al. Serum Tumor Marker CA 15.3 and Stage are the Two Most Powerful Predictors of Survival in Primary Breast Cancer , 2002, Breast Cancer Research and Treatment.
[61] E. B. Polevaia,et al. [Tumor markers in breast cancer]. , 1985, Sovetskaia meditsina.
[62] M. Duffy,et al. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.
[63] O. Merimsky,et al. Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial , 2004, Cancer Chemotherapy and Pharmacology.
[64] M. Duffy,et al. Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations , 2005, Tumor Biology.
[65] A. Liberati,et al. Follow-up strategies for women treated for early breast cancer. , 2000, The Cochrane database of systematic reviews.
[66] D. Kufe,et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. , 2004, Cancer cell.
[67] K. Holli,et al. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. , 2002, European journal of cancer.
[68] R. Rubens,et al. Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.